XML 13 R6.htm IDEA: XBRL DOCUMENT v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows used in operating activities:    
Net income (loss) $ (12,250) $ (6,201)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 223 325
Amortization of deferred financing costs and debt discount   20
Share-based compensation expense 300 297
Noncash financing expenses 3,061 3,545
Change in fair value of derivative instruments 2,631 (4,694)
Accretion of discount on short-term investments (22) (23)
Reduction in the carrying amount of operating lease right-of-use assets 44 63
Gain on sale of assets (16)  
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Grant receivable (450)  
Other current assets (265) 335
Accounts payable and accrued expenses (5,181) 360
Change in operating lease liabilities (45) (63)
Deferred grant liability   373
Net cash used in operating activities (11,970) (5,663)
Cash flows used in investing activities:    
Purchases of property and equipment (10) (121)
Purchase of short-term investments (7,756) (3,500)
Redemption of short-term investments 6,662  
Purchase of intangible assets   (545)
Proceeds from sale of property and equipment 30  
Net cash used in investing activities (1,074) (4,166)
Cash flows provided by financing activities:    
Principal payments of term loan obligation   (3,996)
Proceeds from credit facility   3,292
Repayment of line of credit facility (3,292)  
Repayment of notes payable (3,703)  
Issuance of notes payable and warrants 3,738  
Proceeds from exercise of Series B Warrants from May 2024 PIPE 882  
Purchase of treasury stock   (374)
Proceeds from sale of common stock, pre-funded warrants and warrants 15,001 7,310
Proceeds from sale of common stock under Lincoln Park Purchase Agreement 2,795  
Costs from sale of common stock (220) (45)
Net cash provided by financing activities 15,201 6,187
Net increase (decrease) in cash and cash equivalents 2,157 (3,642)
Cash and cash equivalents at beginning of period 76 8,554
Cash and cash equivalents at end of period 2,233 4,912
Cash paid during period for:    
Interest 539 32
Supplemental schedule of non-cash investing and financing activities:    
Exchange of warrants for notes payable 3,694  
Redemption of notes by issuance of common stock, pre-funded warrants and warrants 3,512  
Unpaid offering cost $ 252 $ 375